How I treat with maintenance therapy after allogeneic HCT
Z DeFilipp, YB Chen - Blood, 2023 - ashpublications.org
Disease relapse is the leading cause of failure for patients receiving allogeneic
hematopoietic cell transplantation (allo-HCT). Maintenance therapy administered after allo …
hematopoietic cell transplantation (allo-HCT). Maintenance therapy administered after allo …
Current donor selection strategies for allogeneic hematopoietic cell transplantation
OA Timofeeva, MC Philogene, QJ Zhang - Human Immunology, 2022 - Elsevier
Since the first allogeneic hematopoietic stem cell transplantation (HCT) was performed by
Dr. E. Donnall Thomas in 1957, the field has advanced with new stem cell sources, immune …
Dr. E. Donnall Thomas in 1957, the field has advanced with new stem cell sources, immune …
Haploidentical vs matched unrelated donors for patients with ALL: donor age matters more than donor type
RS Mehta, D Marin, A Alousi, CG Kanakry… - Blood …, 2023 - ashpublications.org
Haploidentical hematopoietic cell transplantation (HCT) with posttransplant
cyclophosphamide (PTCy) graft-versus-host-disease (GVHD) prophylaxis yields a similar …
cyclophosphamide (PTCy) graft-versus-host-disease (GVHD) prophylaxis yields a similar …
Updated trends in hematopoietic cell transplantation in the United States with an additional focus on adolescent and young adult transplantation activity and outcomes
Hematopoietic cell transplantation (HCT) has been successfully used to treat many
malignant and nonmalignant conditions. As supportive care, donor selection, and treatment …
malignant and nonmalignant conditions. As supportive care, donor selection, and treatment …
Second haploidentical stem cell transplantation (HAPLO-SCT2) after relapse from a first HAPLO-SCT in acute leukaemia—a study on behalf of the Acute Leukaemia …
G Filippini Velázquez, M Labopin, J Tischer… - Bone Marrow …, 2023 - nature.com
For patients with acute myeloid and lymphoblastic leukaemia (AML/ALL) lacking a matched
sibling or unrelated donor, haploidentical stem cell transplantation (HAPLO-SCT) is …
sibling or unrelated donor, haploidentical stem cell transplantation (HAPLO-SCT) is …
Younger Matched Unrelated Donors Confer Decreased Relapse Risk Compared to Older Sibling Donors in Older Patients with B Cell Acute Lymphoblastic Leukemia …
MB Abid, N Estrada-Merly, MJ Zhang, K Chen… - … and Cellular Therapy, 2023 - Elsevier
Although allogeneic hematopoietic cell transplantation (alloHCT) offers cure for older
patients with acute lymphoblastic leukemia (ALL), disease relapse remains a major issue …
patients with acute lymphoblastic leukemia (ALL), disease relapse remains a major issue …
Double filtration plasmapheresis combined with rituximab for donor‐specific antibody desensitization in haploidentical haematopoietic stem cell transplantation
L Liu, X Ji, P Zhu, L Yang, J Shi, Y Zhao… - British Journal of …, 2023 - Wiley Online Library
Donor‐specific anti‐HLA antibodies (DSA) are a major cause of engraftment failure in
patients receiving haploidentical haematopoietic stem cell transplantation (Haplo‐HSCT) …
patients receiving haploidentical haematopoietic stem cell transplantation (Haplo‐HSCT) …
In 2022, which is preferred: haploidentical or cord transplant?
A Nagler, M Mohty - Hematology, 2022 - ashpublications.org
Allogeneic hematopoietic stem cell transplantation is the treatment of choice for high-risk
hematological malignancies such as acute myeloid and lymphocytic leukemia …
hematological malignancies such as acute myeloid and lymphocytic leukemia …
[HTML][HTML] Hematopoietic stem cell transplantation activity in China 2020–2021 during the SARS-CoV-2 pandemic: A report from the Chinese blood and marrow …
LP Xu, DP Lu, DP Wu, EL Jiang, DH Liu… - … and Cellular Therapy, 2023 - Elsevier
ABSTRACT Between 2020 and 2021, 31,525 hematopoietic stem cell transplantations
(HSCTs) were reported to the Chinese Blood and Marrow Transplantation Registry Group …
(HSCTs) were reported to the Chinese Blood and Marrow Transplantation Registry Group …
[HTML][HTML] Haploidentical versus matched unrelated versus matched sibling donor hematopoietic cell transplantation with post-transplantation cyclophosphamide
RS Mehta, RM Saliba, S Ghanem, AM Alousi… - … and Cellular Therapy, 2022 - Elsevier
With the use of post-transplantation cyclophosphamide (PTCy), the outcomes of mismatched
related donor hematopoietic cell transplantation (HCT) are now approaching those of …
related donor hematopoietic cell transplantation (HCT) are now approaching those of …